vTv Therapeutics Q2 2024 Earnings Report

vTv Therapeutics EPS Results

• Actual EPS: -$0.81
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

vTv Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

vTv Therapeutics Announcement Details

• Quarter: Q2 2024
• Date: 8/8/2024
• Time: N/A
• Conference Call Date: Thursday, August 8, 2024
• Conference Call Time: 8:00AM ET

vTv Therapeutics (NASDAQ:VTVT), Inc. is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease. In parallel, vTv is advancing TTP399, a liver-selective glucokinase activator designed as an adjunctive therapy for type 1 diabetes. These programs exemplify vTv’s strategy of targeting high-need indications with differentiated oral therapies.

Since its inception, vTv Therapeutics has pursued strategic collaborations and licensing agreements to support its clinical development efforts and potential commercialization. While primarily operating in the United States, the company actively seeks global partnerships to extend the reach of its pipeline. Led by a management team with extensive experience in pharmaceutical research, clinical development and regulatory affairs, vTv remains committed to progressing its candidates through pivotal trials toward regulatory approval.